Brown Brothers Harriman & Co’s GSK GSK Stock Holding History

Brown Brothers Harriman & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$301K	Buy	5,751 +1,048	+22%	+$55.4K	﹤0.01%	787
2026 Q1	$260K	Sell	4,703 -1,203	-20%	-$65.2K	﹤0.01%	763
2025 Q4	$290K	Buy	5,906 +1,382	+31%	+$64.5K	﹤0.01%	662
2025 Q3	$195K	Sell	4,524 -2,044	-31%	-$79.8K	﹤0.01%	696
2025 Q2	$252K	Buy	6,568 +514	+8%	+$19.6K	﹤0.01%	589
2025 Q1	$235K	Hold	6,054	–	–	﹤0.01%	528
2024 Q4	$205K	Hold	6,054	–	–	﹤0.01%	577
2024 Q3	$247K	Sell	6,054 -1,354	-18%	-$55.4K	﹤0.01%	547
2024 Q2	$285K	Sell	7,408 -441	-6%	-$18.6K	﹤0.01%	484
2024 Q1	$336K	Sell	7,849 -376	-5%	-$15.5K	﹤0.01%	431
2023 Q4	$305K	Sell	8,225 -4	-0%	-$144	﹤0.01%	426
2023 Q3	$298K	Sell	8,229 -401	-5%	-$14.2K	﹤0.01%	421
2023 Q2	$308K	Buy	8,630 +254	+3%	+$9.11K	﹤0.01%	400
2023 Q1	$298K	Buy	8,376 +416	+5%	+$14.6K	﹤0.01%	410
2022 Q4	$280K	Hold	7,960	–	–	﹤0.01%	404
2022 Q3	$234K	Buy	7,960 +138	+2%	+$5.23K	﹤0.01%	427
2022 Q2	$426K	Buy	7,822 +26	+0.3%	+$1.44K	﹤0.01%	342
2022 Q1	$424K	Buy	7,796 +2,708	+53%	+$147K	﹤0.01%	366
2021 Q4	$280	Buy	5,088 +175	+4%	+$9.1K	﹤0.01%	422
2021 Q3	$235	Hold	4,913	–	–	﹤0.01%	422
2021 Q2	$245	Sell	4,913 -201	-4%	-$9.66K	﹤0.01%	405
2021 Q1	$228	Sell	5,114 -1,700	-25%	-$77.2K	﹤0.01%	392
2020 Q4	$313K	Buy	6,814 +79	+1%	+$3.63K	﹤0.01%	364
2020 Q3	$317K	Sell	6,735 -310	-4%	-$15.5K	﹤0.01%	321
2020 Q2	$359K	Buy	7,045 +1,807	+34%	+$92.7K	﹤0.01%	301
2020 Q1	$248K	Sell	5,238 -3,941	-43%	-$210K	﹤0.01%	319
2019 Q4	$539K	Buy	9,179 +2,197	+31%	+$122K	﹤0.01%	299
2019 Q3	$372K	Sell	6,982 -4,078	-37%	-$210K	﹤0.01%	320
2019 Q2	$553K	Buy	11,060 +1,164	+12%	+$58.4K	﹤0.01%	271
2019 Q1	$517K	Buy	9,896 +4,871	+97%	+$243K	﹤0.01%	260
2018 Q4	$240K	Sell	5,025 -320	-6%	-$15.8K	﹤0.01%	320
2018 Q3	$268K	Buy	5,345 +112	+2%	+$5.69K	﹤0.01%	314
2018 Q2	$264K	Sell	5,233 -614	-11%	-$30.9K	﹤0.01%	305
2018 Q1	$286K	Hold	5,847	–	–	﹤0.01%	294
2017 Q4	$259K	Hold	5,847	–	–	﹤0.01%	307
2017 Q3	$297K	Hold	5,847	–	–	﹤0.01%	278
2017 Q2	$315K	Hold	5,847	–	–	﹤0.01%	274
2017 Q1	$308K	Sell	5,847 -20	-0.3%	-$1.01K	﹤0.01%	277
2016 Q4	$282K	Buy	5,867 +20	+0.3%	+$988	﹤0.01%	259
2016 Q3	$315K	Sell	5,847 -280	-5%	-$15.4K	﹤0.01%	261
2016 Q2	$332K	Buy	6,127 +120	+2%	+$6.32K	﹤0.01%	267
2016 Q1	$304K	Hold	6,007	–	–	﹤0.01%	269
2015 Q4	$303K	Sell	6,007 -886	-13%	-$45.2K	﹤0.01%	282
2015 Q3	$331K	Buy	6,893 +95	+1%	+$4.95K	﹤0.01%	279
2015 Q2	$354K	Sell	6,798 -2,978	-30%	-$168K	﹤0.01%	288
2015 Q1	$564K	Buy	9,776 +880	+10%	+$50.5K	﹤0.01%	243
2014 Q4	$475K	Sell	8,896 -731	-8%	-$40.9K	﹤0.01%	260
2014 Q3	$553K	Buy	9,627 +671	+7%	+$41.1K	﹤0.01%	251
2014 Q2	$599K	Buy	8,956 +1,499	+20%	+$101K	﹤0.01%	251
2014 Q1	$498K	Buy	7,457 +400	+6%	+$27K	﹤0.01%	245
2013 Q4	$471K	Sell	7,057 -80	-1%	-$5.19K	﹤0.01%	248
2013 Q3	$448K	Sell	7,137 -4,985	-41%	-$321K	﹤0.01%	251
2013 Q2	$757K	Buy	+12,122	New	+$769K	﹤0.01%	238

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Brown Brothers Harriman & Co's GSK Position: Q2 2026 in Review

Brown Brothers Harriman & Co increased its GSK (GSK) stake by 22% in Q2 2026, buying an estimated $55.4K and bringing the position to 5,751 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #787.

Brown Brothers Harriman & Co first reported a position in GSK in Q2 2013 and has held it in 53 quarters since. The position peaked at $757K in Q2 2013. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Brown Brothers Harriman & Co held 5,751 shares of GSK worth $301K as of Q2 2026.
Brown Brothers Harriman & Co bought 1,048 GSK shares in Q2 2026, an estimated $55.4K.
GSK made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #787 holding.
Brown Brothers Harriman & Co first reported a position in GSK in Q2 2013 and has held it in 53 quarters since.
Brown Brothers Harriman & Co's GSK position peaked at $757K in Q2 2013.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.